^Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R.; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia". Neuropsychopharmacology. 32 (1): 17–34. doi:10.1038/sj.npp.1301188. PMID16936709.
^Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney, F. O.; Léonardon, J.; Granger, P.; Debono, M. W.; Bohme, G. A.; Sgard, F. D. R.; Besnard, F. O.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vigé, X.; Voltz, C.; Rouquier, L.; Souilhac, J.; Santucci, V.; Gueudet, C.; Françon, D.; Steinberg, R. G.; Griebel, G.; Oury-Donat, F. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology. 32 (1): 1–16. doi:10.1038/sj.npp.1301189. PMID17019409.
^Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711". Biological Psychiatry. 63 (1): 92–97. doi:10.1016/j.biopsych.2007.04.034. PMID17601496.
^Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). "Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia". Neuropsychopharmacology. 34 (7): 1753–1763. doi:10.1038/npp.2008.232. PMID19158670.
